Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00524030 · ClinicalTrials.gov registry record · Phase 3
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- Phase 3
- Development phase
- 161
- Enrollment target
NCT00524030 is a Phase 3 study that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 161 participants.
The verdict
NCT00524030, a Phase 3 study, was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 161 participants
- Enrollment target
Study Summary
This study will determine the safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy subjects for the treatment of partial seizures. The duration of the trial is about 6 months.
Interventions
- DRUG pregabalin 600 mg/day
- DRUG pregabalin 150 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00524030
The ClinicalTrials.gov registry entry for NCT00524030 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pregabalin 600 mg/day is the first listed.
NCT00524030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00524030 about?
NCT00524030 is a clinical study titled "Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures". This study will determine the safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy subjects for the treatment of partial seizures. The duration of the trial is about 6 months.
What is the current status of trial NCT00524030?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2007-09. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00524030?
The interventions under investigation include: pregabalin 600 mg/day (DRUG), pregabalin 150 mg/day (DRUG).
Who is sponsoring clinical trial NCT00524030?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.